Renoprotective effects of potassium supplementation in chronic kidney disease

Recruiting

• Conditions: Chronic kidney disease; chronic renal insufficiency; 10029149

• Registration Number: NL-OMON53024
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 532

Inclusion Criteria

- Adult patients with CKD stage 3b or 4
- Fall in eGFR > 2 ml/min/1.73 m2/year in preceding years
- Hypertension (automated blood pressure > 140/90 mmHg or use of
anti-hypertensive medication)

Exclusion Criteria

- Hyperkalemia (serum potassium > 5.5 mmol/l) at study visit V0
- Medical reasons to continue dual RAAS-blockade, mineralocorticoid receptor
blockers, potassium-sparing diuretics, or oral potassium binders.
- Patients using calcineurin inhibitors
- Patients using tolvaptan
- Kidney transplant recipients
- Patients with an active gastro-intestinal ulcus
- Patients with previous history of ventricular cardiac arrhythmia
- Patients with a life expectancy < 6 months
- Expected initiation of renal replacement therapy < 2 years
- Incapacitated subjects or subjects who are deemed unfit to adequately adhere
to instructions from the research team
- Women who are pregnant, breastfeeding or consider pregnancy in the coming 2
years.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>2-year change in eGFR (renal outcome). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Effects on 24-hour blood pressure, albuminuria, cardiovascular markers, and<br /><br>incidence of hyperkalemia</p><br>